These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23435190)

  • 1. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.
    Kopczynski C; Novack GD; Swearingen D; van Haarlem T
    Br J Ophthalmol; 2013 May; 97(5):567-72. PubMed ID: 23435190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers.
    Levy B; Ramirez N; Novack GD; Kopczynski C
    Am J Ophthalmol; 2015 May; 159(5):980-5.e1. PubMed ID: 25637177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
    Uusitalo H; Kaarniranta K; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
    Raber S; Courtney R; Maeda-Chubachi T; Simons BD; Freedman SF; Wirostko B;
    Ophthalmology; 2011 Oct; 118(10):2022-7. PubMed ID: 21788077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.
    Tanihara H; Inatani M; Honjo M; Tokushige H; Azuma J; Araie M
    Arch Ophthalmol; 2008 Mar; 126(3):309-15. PubMed ID: 18332309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.
    Katz LJ; Cohen JS; Batoosingh AL; Felix C; Shu V; Schiffman RM
    Am J Ophthalmol; 2010 Apr; 149(4):661-671.e1. PubMed ID: 20346780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
    Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
    Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.